Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Company Overview - Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for serious unmet medical needs in oncology [2] - The company has two clinical-stage drug candidates: NXP900 and NXP800 [2] Drug Candidates - NXP900 is an oral small molecule inhibitor targeting the SRC Family of Kinases (SFK), including SRC and YES1, with a unique mechanism that inhibits both catalytic and scaffolding functions [2] - NXP900 has completed a Phase 1a dose escalation study, and the Phase 1b program has been initiated [2] - NXP800 is an oral small molecule GCN2 activator that has shown anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer, with potential exploration in other cancer types [2] Upcoming Events - Senior management will participate in the H.C. Wainwright Global Investment Conference, with a corporate presentation available for on-demand viewing starting September 5, 2025 [1] - The conference will take place from September 8-10, 2025, where the company will also attend virtual one-on-one meetings [1]